Citations

Mayo Clinic

Showing 10 of 108585 citations.

Plasma Methylated DNA Markers for Melanoma Surveillance
Berger, Calise K. , Mahoney, Douglas W. , Burger, Kelli N. , Doering, Karen A. , Gonser, Anna M. , Cao, Xiaoming , Heilberger, Justin, Gysbers, Brianna J. , Kottschade, Lisa A. , Lehman, Julia S. , Katerov, Viatcheslav E. , Allawi, Hatim T. , Meves, Alexander , Mahoney, Douglas W , Doering, Karen A , Gysbers, Brianna J , Kottschade, Lisa A , Lehman, Julia S , Katerov, Viatcheslav E , Meves, Alexander , Berger, Calise K , Taylor, William R. , Foote, Patrick H. , Markovic, Svetomir N. , Kisiel, John B.

JCO Precision Oncology | October 26, 2023 | Volume: No volume available | Issue: 7 | Pages: No page available

10.1200/po.23.00389 | PMID 37883729 Get It

Plasma-based MDMs may offer a cost-effective alternative to imaging for melanoma detection. Early results show 80% sensitivity and 100% specificity against cancer-free controls. Further study needed. #MelanomaResearch #EarlyDetection
Deep and Repeated Response to Trastuzumab Deruxtecan in a Patient With Human Epidermal Growth Factor Receptor 2–Amplified Large-Cell Neuroendocrine Carcinoma With Brain Metastases: A Case Report
Algarin-Perneth, Sandra , Suleiman, Riham , Abeykoon, Jithma P. , Hálfdánarson, Þorvarður R. , Yi, Joanne, Peikert, Tobias, McGarrah, Patrick W. , Halfdanarson, Thorvardur R , Fuentes-Bayne, Harry E, Yi, Joanne E, McGarrah, Patrick , Fuentes, Harry E

JCO Precision Oncology | October 26, 2023 | Volume: No volume available | Issue: 7 | Pages: No page available

10.1200/po.23.00242 | PMID 37883722 Get It

Metastatic CUP is complex, especially NCUP. Precision oncology is crucial for rare, aggressive cancers. A 54-year-old had HER2+ neuroendocrine carcinoma of unknown origin. T-DXd treatment, response, re-challenge show importance of genomics and caution.
Shared decision making in young elite and professional athletes: pros and pitfalls
Pelliccia, Antonio , Larson, Kathryn, Larson, Kathryn F.

European Journal of Preventive Cardiology | October 26, 2023 | Volume: 31 | Issue: 12 | Pages: e86-e88

10.1093/eurjpc/zwad339 | PMID 37883716 Get It

Are body mass index changes related to incident atrial fibrillation?—Results of the Danish Diet, Cancer, and Health Cohort
Medina‐Inojosa, Betsy J. , López-Jiménez, Francisco , Lopez-Jimenez, Francisco , Medina-Inojosa, Betsy

European Journal of Preventive Cardiology | October 26, 2023 | Volume: 31 | Issue: 2 | Pages: 214-215

10.1093/eurjpc/zwad333 | PMID 37883698 Get It

A Year in Review: 2023
Baudhuin, Linnea M. , Park, Jason Y. , Young, Ian Stuart

Clinical Chemistry | October 26, 2023 | Volume: 69 | Issue: 12 | Pages: 1327-1328

10.1093/clinchem/hvad178 Get It

Normal and Abnormal Appearances of the Ovaries during Assisted Reproduction: Multimodality Imaging Review
Smith, Katherine , Parvinian, Ahmad , Packard, Annie T. , Smith, Katherine A , Ainsworth, Alessandra J. , Shenoy, Chandra C. , Packard, Ann T.

RadioGraphics | October 26, 2023 | Volume: 43 | Issue: 11 | Pages: No page available

10.1148/rg.230089 | PMID 37883303 Get It

Eruptive Papules as a Cutaneous Manifestation of Metastatic Prostate Adenocarcinoma
Onalaja-Underwood, Amanda A. , Sokumbi, Olayemi

The American Journal of Dermatopathology | October 26, 2023 | Volume: 45 | Issue: 12 | Pages: 828-830

10.1097/dad.0000000000002559 | PMID 37883967 Get It

Abstract: Cutaneous metastasis from prostate cancer is a rare manifestation, occurring in less than 1% of all cases of prostate cancer. Prostate cancer metastasis occurs most often in lymph nodes and bones. In this study, we present the case of a 55-year-old man with prostate adenocarcinoma and progressive papules on his left chest that developed shortly after androgen deprivation therapy was initiated. This case emphasizes the significance of considering cutaneous metastasis in the diagnostic differential when assessing patients with a history of cancer and the need to thoroughly evaluate these cases.
Ein globaler Consensus zu Definitionen, Diagnostik und Behandlungsmanagement des fibrostenotischen Morbus Crohn des terminalen Ileums
Baker, Mark E. , Bemelman, Willem A. , D’Haens, Geert , D’Hoore, A., Feakins, Roger , Fleshner, Phillip , Ha, Christina , Lyu, R., Mao, Ren , Sandborn, William J. , Ng, S, Silverberg, Mark S. , Bruining, David H. , Feagan, Brian G. , Bettenworth, Dominik , Fletcher, Joel G. , Jairath, Vipul , Lu, Cathy , Dignass, Axel , Dotan, Iris , Henderson, G., Panés, Julián , Rogler, Gerhard , Rimola, Jordi , Siegmund, Britta , Taylor, Stuart A. , Verstockt, Bram , Gordon, Ilyssa O. , Rieder, F.

Zeitschrift für Gastroenterologie | October 26, 2023 | Volume: 61 | Issue: 08 | Pages: e421-e422

10.1055/s-0043-1771750 Get It

Tailored doses, tailored savings: Optimizing dosing strategies of immune checkpoint inhibitors.
Das, Devika , Desai, Aakash , Jensen, Chelsee , Soefje, Scott A. , Hussaini, S. M. Qasim , Sridhar, Arthi

JCO Oncology Practice | October 26, 2023 | Volume: 19 | Issue: 11_suppl | Pages: 68-68

10.1200/op.2023.19.11_suppl.68 Get It

68 Background: While immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, their high cost and limited global supply pose major challenges. Optimizing ICI dosing to achieve a minimum effective dose that has shown to maintain clinical benefit may be a potential solution with significant savings to the health system. We investigated potential savings in Medicare that could be attained from alternative ICI dosing. Methods: We conducted a literature review including original Phase 1/2 trials describing the minimal effective dose of three commonly used ICIs: Pembrolizumab (P), Nivolumab (N) and Atezolizumab (A). Alternate dosing strategies based on existing data for Pembrolizumab (2 mg/kg), Nivolumab (1 mg/kg) and Atezolizumab (4 mg/kg) were proposed. Publicly available CMS data on Medicare Part B expenditure for these therapies was utilized to obtain average cost per dosage unit, mg/dosage unit, and number of Medicare beneficiaries between 2018-2021. Average cost per dose and total cost per ICI was calculated based on current FDA approved dosing and alternate dosing strategies. Results: The average wholesale cost per fixed dose for P (200 mg), N (480 mg), and A were $9,242.00, $12,460.80, and $8,616.00, respectively. Implementing the proposed alternate dosing strategies led to a substantial reduction in drug costs: P ($7,393.60), N ($2,076.80), and A ($2,297.60). The ensuing cost savings were calculated based on the annual number of Medicare beneficiaries. From 2018-2021, the average total savings were estimated to be $95,545,182 for Pembrolizumab, $294,734,264 for Nivolumab, and $62,937,582 for Atezolizumab (Table). The cumulative average total cost savings from 2018-2021 exceeded $453 million. Conclusions: We demonstrate potential savings in Medicare with implementation of an alternative ICI dosing strategy. Our study underscores an urgent need to better understand clinical efficacy and cost savings from a patient perspective, and feasibility from a regulatory standpoint. This perspective may hold considerable global implications, providing a roadmap for cost-effective care in the domain of immunotherapy. [Table: see text]